Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

Fig. 6

Clinical evaluation of EGFR and BCL-2/XL co-expression. Forty-six triple-negative breast cancers were evaluable for EGFR, BCL-2, and BCL-XL co-expression analysis. The graphs depict the co-expression of either BCL-2:EGFR (a) or BCL-XL:EGFR (b). Each symbol represents an individual clinical case (TN#). Each case is colored and or labeled for comparison purposes. H-scores [0–300] are presented for EGFR and BCL-2/XL

Back to article page